Objectives To analyze predictive clinical factors of survival in bone‐metastatic prostate
cancer, and to develop a prognostic nomogram for patients with this condition. Methods The …

Background The paradigm change observed over the last few years in several solid tumors
emphasizes the value of locoregional treatment in the presence of metastatic disease …

Background The role of local treatment (LT) in patients with metastatic prostate cancer
(mPCa) at diagnosis is controversial. Objective We set to evaluate the potential impact of LT …

Aims: The aim is to assess for a difference in the incidence of metastasis (IM) and prostate-
specific antigen (PSA) levels at diagnosis in patients with Gleason score (GS) 3+ 4 versus …

Morbidity and mortality due to prostate cancer are mainly a result of prostate cancer
metastases. After the initial neoplastic transformation of cells, the process of metastasis …

Background Prostate cancer exhibits biological and clinical heterogeneity even within
established clinico-pathologic risk groups. The Decipher genomic classifier (GC) is a …

Background Men who present with metastatic disease can have de novo or primary
progressive disease. We characterized and compared the outcomes between these 2 …

Purpose/Objectives Treatment of the primary tumor reportedly improves survival in several
types of metastatic cancer. We herein evaluated the efficacy and toxicity of radiotherapy for …

Purpose: We used a propensity risk scoring approach to model long-term survival for men
with clinically localized prostate cancer. We developed comprehensive lookup tables for …

PURPOSE: Transition zone (TZ) cancers are reported to have better biochemical relapse-
free survival (bRFS) after radical prostatectomy (RP) than cancers from the peripheral zone …